




<http://www.uib.no/med/angiotargeting/>



# MR Imaging of Malignant Brain Tumor Models in Rodents

Frits Thorsen

Dept. of Biomedicine, University of Bergen, Norway



# Overview


1. Introduction to malignant brain tumors.
2. Rat model: Intracranial implantations of human brain metastasis.
3. Mouse model: Intracardial injections of human melanoma cells.
4. Mouse model: Intradermal injections of human melanoma cells.
5. Can single tumor cells be tracked in vivo?




1. **Introduction to malignant brain tumors.**
2. Rat model: Intracranial implantations of human brain metastasis.
3. Mouse model: Intracardial injections of human melanoma cells.
4. Mouse model: Intradermal injections of human melanoma cells.
5. Can single tumor cells be tracked in vivo?




# Primary and secondary brain tumors



Ellison & Love: Neuropathology 2e © 2004 Elsevier Ltd.




Brain met from lung cancer



Brain met from endometrial cancer



# Cancer and the metastatic process




1. Introduction to malignant brain tumors.
2. **Rat model: Intracranial implantations of human brain metastasis.**
3. Mouse model: Intracardial injections of human melanoma cells.
4. Mouse model: Intradermal injections of human melanoma cells.
5. Can single tumor cells be tracked in vivo?



# Collection of metastases

Brain metastases from patients are collected during operation, minced, and put in culture. After 2-4 weeks, tumor spheroids are implanted stereotactically into brains of immunodeficient animals.



# Intracranial tumor take

| Patient | Diagnosis of primary disease                   | i.c. tumour take<br>[# of tumor take/<br># of animals] | Animal survival<br>[mean # of days $\pm$ SD] | s.c. tumor take<br>[# of tumor take/<br># of implanted animals] | Number of passages<br>in animals<br>[# of tumor take/<br># of animals last passage] | Animal survival at<br>last passage<br>[mean # of days $\pm$ SD] |
|---------|--|--|--|---|---|---|
| 1       | Serous papillary adenocarcinoma from ovary     | Yes [1/2]  | 212  | n.d.  | 2 [1/1]   | 156   |
| 2       | Serous papillary adenocarcinoma from ovary     | Yes [3/4]  | 102 $\pm$ 30                                 | n.d.  | n.d.  | n.d.  |
| 3       | Adenocarcinoma from colon                      | Yes [6/6]  | 55 $\pm$ 15                                  | n.d.  | 4 [6/6]   | 41 $\pm$ 15   |
| 4       | Large cell neuroendocrine carcinoma from colon | Yes [7/7]  | 55 $\pm$ 9                                   | n.d.  | 3 [4/4]   | 30 $\pm$ 3  |
| 5       | Malignant melanoma from skin                   | Yes [7/7]  | 27 $\pm$ 7                                   | n.d.  | 2 [2/2]   | 120 $\pm$ 132   |
| 6       | Malignant melanoma from skin                   | No [0/4]   | -  | n.d.  | n.d.  | n.d.  |
| 7       | Malignant melanoma from skin                   | Yes [1/4]  | 94   | No [0/3]  | n.d.  | n.d.  |
| 8       | Squamous carcinoma from lung                   | No [0/4]   | -  | No [0/2]  | n.d.  | n.d.  |
| 9       | Non-small cell adenocarcinoma from lung        | Yes [3/4]  | 32 $\pm$ 9                                   | No [0/2]  | n.d.  | n.d.  |

Abbreviations: i.c., intracranial; s.c., subcutaneous; n.d., not done; -, no data.



# Primary Abs and Dilutions Used

| Antibodies  | Clone               | Dilution | Source                                      |
|-------------|---------------------|----------|---|
| CK7         | OV-TL 12/30         | 1:100    | DAKOCytomation (Glostrup, DK)               |
| CK20        | K <sub>S</sub> 20.8 | 1:1000   | DAKOCytomation                              |
| CA125       | OC125               | 1:50     | DAKOCytomation                              |
| CEA         | II7                 | 1:400    | DAKOCytomation                              |
| ER $\alpha$ | 1D5                 | 1:50     | DAKOCytomation                              |
| PR          | PgR 636             | 1:150    | DAKOCytomation                              |
| Melan-A     | A103                | 1:50     | DAKOCytomation                              |
| HMB45       |                     | 1:100    | DAKOCytomation                              |
| S100        |                     | 1:3000   | DAKOCytomation                              |
| Vimentin    | V9                  | 1:1000   | DAKOCytomation                              |
| TTF1        | 8G7G3/1             | 1:100    | DAKOCytomation                              |
| CD56        | 1B6                 | 1:25     | Novocastra Laboratories Ltd (Newcastle, UK) |
| NSE         | BBS/NC/VI-H14       | 1:1000   | DAKOCytomation                              |
| Syn         |                     | 1:150    | DAKOCytomation                              |
| CgA         |                     | 1:3000   | DAKOCytomation                              |
| p53         | DO-7                | 1:1000   | DAKOCytomation                              |

CEA: Carcinoembryonic antigen; ER $\alpha$ : Estrogen receptor  $\alpha$ ; PR: progesterone receptor; TTF1: Thyroid transcriptional factor 1; NSE: Neuron specific enolase; Syn: Synaptophysin; CgA: Chromogranin A.



# Tumor marker expression

| Tumor Marker | Patient 1<br>Ovarian cancer |     |     | Patient 2<br>Ovarian cancer |     |     | Patient 3<br>Colon cancer |     |     | Patient 4<br>Colon cancer |     |     | Patient 5<br>Skin cancer |     |     | Patient 9<br>Lung cancer |     |     |
|--------------|-----------------------------|-----|-----|-----------------------------|-----|-----|---------------------------|-----|-----|---------------------------|-----|-----|--------------------------|-----|-----|--------------------------|-----|-----|
|              | PT                          | PM  | RM  | PT                          | PM  | RM  | PT                        | PM  | RM  | PT                        | PM  | RM  | PT                       | PM  | RM  | PT                       | PM  | RM  |
| CK7          | +++                         | +++ | nt  | +++                         | +++ | +++ | -                         | -   | -   | +++                       | +++ | +   | nt                       | -   | -   | +++                      | +++ | -   |
| CK20         | -                           | -   | -   | -                           | -   | -   | +++                       | nt  | +++ | +++                       | +   | -   | nt                       | -   | -   | -                        | -   | -   |
| CA125        | +++                         | +++ | nt  | +++                         | +++ | +++ | -                         | -   | -   | -                         | -   | -   | nt                       | -   | -   | -                        | -   | -   |
| CEA          | -                           | -   | nt  | -                           | -   | -   | +++                       | +++ | +++ | +++                       | +++ | +++ | nt                       | -   | -   | -                        | -   | -   |
| ER           | ++                          | ++  | nt  | +                           | +   | -   | -                         | -   | -   | -                         | -   | -   | nt                       | -   | -   | -                        | -   | -   |
| PR           | +                           | +   | nt  | +                           | +   | +++ | -                         | -   | -   | -                         | -   | -   | nt                       | -   | -   | -                        | -   | -   |
| Melan-A      | -                           | -   | -   | -                           | -   | -   | -                         | nt  | -   | -                         | -   | -   | +++                      | -   | +   | -                        | -   | -   |
| HMB45        | -                           | -   | nt  | -                           | -   | -   | -                         | -   | -   | -                         | -   | -   | -                        | -   | -   | -                        | -   | -   |
| S100         | +                           | -   | nt  | +                           | +   | +   | -                         | -   | -   | -                         | +   | +   | +++                      | +   | +   | -                        | ++  | -   |
| Vimentin     | -                           | -   | nt  | +                           | +   | -   | -                         | -   | -   | -                         | -   | -   | nt                       | +++ | +++ | -                        | +++ | +++ |
| TTF1         | -                           | -   | nt  | -                           | -   | -   | -                         | nt  | -   | -                         | -   | -   | nt                       | -   | -   | -                        | ++  | -   |
| CD56         | -                           | +   | nt  | ++                          | +   | +   | -                         | -   | -   | +++                       | +++ | ++  | nt                       | -   | -   | ++                       | +   | -   |
| NSE          | -                           | -   | nt  | +                           | -   | -   | -                         | -   | -   | ++                        | ++  | +   | nt                       | ++  | -   | +                        | +   | -   |
| Syn          | +                           | -   | nt  | -                           | +   | +   | +                         | +   | -   | +++                       | +++ | +++ | nt                       | -   | -   | -                        | -   | -   |
| CgA          | -                           | -   | nt  | -                           | -   | -   | -                         | -   | -   | ++                        | +   | -   | nt                       | -   | -   | -                        | -   | -   |
| p53          | +++                         | +++ | +++ | +++                         | +++ | +++ | +++                       | +++ | +++ | +++                       | +++ | +++ | nt                       | +   | +   | +++                      | +   | +   |

Common markers used to discriminate colorectal carcinomas from ovarian adenocarcinomas.

Melanocytic tumor markers.

Commonly used mesenchymal tumor markers.

Lung specific tumor marker.

Neuroendocrine cell markers.

+++ : 70%-100% positive tumor cells




++ : 30%-70% positive tumor cells.

+ : Less than 30% positive tumor cells.


- : No positive tumor cells.

nt : No tumor cells available.



Experimental tumors have similar radiological appearance as in the patients





Primary:  
Colon c.



Primary:  
Ovarian c.



Primary:  
Melanoma




Primary:  
Lung c.




# Brain metastases growth is monitored with MR

MR Scan 08.09.2006



MR Scan 28.09.2006




Primary cancer: Ovarian

RARE T2: TR4200ms, TE36ms, FA180, TA 4m28s800ms, Slice 1/1, NA2, 256X256, FOV3.5



# The metastases are highly angiogenic





MR Scan 28.09.2006. T1 with Gadolinium Contrast



MSME: TR438.5ms, TE10.6ms, FA180, TA 5m36s786ms, Slice 1/1,  
T10, NA3, 256X256, FOV3.5, Fat Sup. On, Mot. Sup. On



# Intratumoral diffusion is increased




## EPI:


TR3000ms, TE33.3ms, FA90, TA5m36s0ms, Slice 1/1, NEX4, 1 diffusion direction, 6 diff. exp. pr direction, 1 A0. B values 100, 200, 400, 600, 800, 1000 s/mm<sup>2</sup>.




# Histology of patient and animal tumor is similar




10X




10X




10X



40X



20X



20X


**Primary Colon Tumor**  
B0117862B

**Patient Brain Metastasis**  
B0620837C


**Rat Brain Metastasis**  
Met2p1B

Morphology like adenocarcinomas of colorectal type. The tumor cells are polymorphic, eosinophilic, showing tubular growth pattern, vacuolated, tumor tissue sharply demarcated to the brain tissue, mitotic figures and necrotic areas are also present.


# Histology of patient and animal tumor is similar




10X




10X




4X



40X



20X



40X

**Primary Ovary Tumor**

**B04158871**

**Patient Brain Metastasis**

**B0615651A**

**Rat Brain Metastasis**

**Met3p1A**

Low differentiated tumor tissue with solid arrangement of polygonal cells with enlarged roundish hyperchromatic nuclei, tight cell cohesion (low differentiated carcinoma). The tumor cells are epithelial, eosinophilic, sometimes clear, polymorphic, with diffuse growth pattern and mitotic figures.





The metastases show high proliferation rates also after serially passaging

### Colon met:

1st Passage



3rd Passage

20X



20X


40X




40X




# Colon mets express Nestin in primary biopsy as well as in serially passaged tumors




Patient biopsy



Passage 1



Passage 3




Negative control

Nestin is a type IV intermediate filament protein.

Expressed (transient) by many cells during development, but does not persist into adulthood.




# DNA Copy Analysis



**B**

|                | Patient | Animal |
|----------------|---------|--------|
| <b>Loss</b>    |         |        |
| 1p36.3p35.1    |         |        |
| 1q42.1q44      |         |        |
| 2p22.3p22.3    |         |        |
| 2p16.1p11.2    |         |        |
| 2q33.3q37.3    |         |        |
| 4              |         |        |
| 8p23.3p11.23   |         |        |
| 14             |         |        |
| 15             |         |        |
| 17p13.3p13.1   |         |        |
| 18             |         |        |
| 19             |         |        |
| 21             |         |        |
| <b>Gain</b>    |         |        |
| Xq21.31        |         |        |
| 2q23.3q33.1    |         |        |
| 7              |         |        |
| 8p11.33q24.3   |         |        |
| 12q24.13q24.33 |         |        |
| 13             |         |        |
| 20             |         |        |
| 22q11.1q11.21  |         |        |






**Only difference:**



Gain in 2q23.3q33.1  
seen in animal met,  
which was not  
present in the  
patient tumor.



# Future work: Gamma Knife irradiation of metastases implanted intracranially in nude rats




# Gamma Knife pilot study



1. Introduction to malignant brain tumors.
2. Rat model: Intracranial implantations of human brain metastasis.
3. **Mouse model: Intracardial injections of human melanoma cells.**
4. Mouse model: Intradermal injections of human melanoma cells.
5. Can single tumor cells be tracked in vivo?



# The skin




In epidermis:

Basal cells  
Squamous cells  
Melanocytes



# Incidence of melanoma in Norway



5 year survival if distant metastasis: 21.9% (females), 6.5% (males).  
In 2007, 177 men and 98 women melanoma deaths were registered.

Source: <http://www.kreftregisteret.no/no/Registrene/Kreftstatistikk/>

# Some risk factors

Exposure to UV radiation.

Fair skin.

Lots of moles on the skin.

Previous melanomas.

History of many sunburns.

Family history.

Being older.


Genetic (5-10%):

CDKN2A (cell cycle regulator).

MC1R (controlling the type of melanin being produced).



# Proposed molecular alterations



Zaidi et al, J Invest Dermatol 2008




# Models of melanoma progression

40-60% of melanoma patients diagnosed with (often multiple) brain metastases.  
Patient survival 4-6 months.

## Available animal models:

Intracarotid injection of murine and human melanoma cell lines in syngeneic mice (Fidler et al, 1999).  
Several murine and human cell lines have been established (see review; Cranmer et al, 2005).  
Grafting human skin onto immunodeficient mice (Zaidi et al, 2008).




We obtained a brain metastases from a patient diagnosed with melanoma. Tumor pieces were put in cell culture. A cell line (H1) developed after 4 weeks.




# The melanoma cells is tumorigenic in the mouse brain

3 animals were stereotactically injected with 1 million H1 cells into the brain of nod/scid mice.


Tumors developed in 2/3 animals after 4 weeks.



T2




T1



T1+contrast



# H1dsRed cell line is established from H1 cells




H1 (neg. Control)

H1\_DsRed unsorted

H1\_DsRed sorted

The H1dsRed cell line is tumorigenic sub. cut.




Tumor by H1dsRed 6 weeks after sub.cut injection in matrigel in eGFP nod/scid mice



# The H1dsRed cell line is tumorigenic in the brain




2 animals were stereotactically injected with 1 million melanoma cells into the brain of eGFP nod/scid mice.

Tumors detected by confocal imaging after 4 weeks.






# Development of H1\_GFP\_Luc cell line

Lentiviral transfection of H1 cell line with genes for GFP and Luciferase.  
The resulting H1\_GFP\_Luc cell line was then sorted by flow cytometry.




↓ Double sorting





# Determination of whether H1\_GFP\_Luc cells are suitable for in vivo bioluminescence imaging

In vitro bioluminescence imaging of H1\_GFP\_Luc cell line




# The H1\_GFP\_Luc cell line is tumorigenic in vivo

6 animals injected intracardially with 1 million H1\_GFP\_Luc cells.





H1\_GFP\_Luc  
Post sorted



Metastases in heart, lung and mandible after 3 weeks.  
Metastases in heart, lung, mandible, brain and lymph nodes were seen after 5 weeks.

5 weeks after injections





Animal 1

Animal 2

Animal 3

Animal 4



# Progression of tumor metastases development


|         |                         |  |
|---------|-------------------------|--|
| 6542_B1 | Week 3                  | Week 5   |
|         | Mandible,<br>femur,lung | Mandible, femur, brain<br>lung,spine,spleen/kidney |

|         |                           |             |                             |  |
|---------|---------------------------|-------------|-----------------------------|--|
| 6543_B2 | Week 3                    | Week4,5     | Week6,7                     | Week 8   |
|         | Heart,lung/<br>lymph-node | Heart, lung | Heart,<br>lung,<br>mandible | Heart, lung,<br>mandible,<br>femur, spine,<br>ovary,<br>kidney,brain |




# Multiple brain metastases detected by MR


Multiple brain metastases were seen on MRI 5 weeks after injection of the H1\_GFP\_Luc cells.



T1w w/contrast




T2 weighted MR image





T1 weighted MR image with contrast

# MRI 7 weeks after injections shows multiple brain mets



# Multiple brain metastases confirmed by histology




## Multiple CNS metastases were seen by histology




Cerebrum




Cerebrum




Pons



Medulla



Cerebellum





Spinal cord





# Multiple metastases were detected also in other organs



Spleen



Os ilium




Heart




# Multiple metastases were detected also in other organs





Liver hilus




Adrenal




Lung




# Expression of tumor markers in brain metastases



## Ovary metastasis cells show strong GFP expression



6543\_B2\_Right\_Ovary\_10X



6543\_B2\_Right\_Ovary\_20X


Ovary metastasis cell line shows strong GFP expression,  
similar to the parent H1\_GFP\_Luc cell line

Ovary cell line established after 2 weeks


Spinal cord and femur metastasis cell lines established after 4 weeks



# Generation of cell line from mouse lung metastasis



6543\_B2\_Right\_Lung\_10X



6543\_B2\_Right\_Lung\_20X

Lung metastasis cell line shows strong GFP expression,  
similar to the parent H1\_GFP\_Luc cell line


Lung metastasis cell line established after 1 week






# Genetic analysis of tumors developing in different organs

Do the melanoma brain metastatic cells also populate other organs than the brain?  
If yes, is it possible to determine common/differentially expressed genes in the process?

Strategy:




Brain  
Bone marrow  
Lung  
Liver




# Organs are currently being dissociated and sorted by FACS



Liver cells presorted




Bone marrow cells presorted




Lung cells presorted



Liver cells postsorted



Bone marrow cells postsorted



Lung cells postsorted



1. Introduction to malignant brain tumors.
2. Rat model: Intracranial implantations of human brain metastasis.
3. Mouse model: Intracardial injections of human melanoma cells.
4. **Mouse model: Intradermal injections of human melanoma cells.**
5. Can single tumor cells be tracked in vivo?



# Intradermal injections of H1\_GFP\_Luc cells



Experiments ongoing

Injections Jan 4<sup>th</sup> 2010  
0.5 million cells/100  $\mu$ l  
7 animals




1. Introduction to malignant brain tumors.
2. Rat model: Intracranial implantations of human brain metastasis.
3. Mouse model: Intracardial injections of human melanoma cells.
4. Mouse model: Intradermal injections of human melanoma cells.
5. **Can single tumor cells be tracked in vivo?**






# Cellular MR Imaging

For cellular MR imaging, cells need to be labeled with MR contrast agents in order to make them stand out from surrounding tissue. The phagocytic activity of certain cell types allows the incorporation of MR contrast agents to visualize their trafficking in vivo.



# In vitro cell proliferation study

Performed on U251 and U373 glioma cells, and H1 metastatic melanoma cells.




|                 | G <sub>0</sub> phase | S phase | G <sub>2</sub> M phase |
|-----------------|----------------------|---------|------------------------|
| U251 control #1 | 47.0 %               | 49.7 %  | 3.3 %                  |
| U251 control #2 | 50.4 %               | 48.5 %  | 1.1 %                  |
| U251 Fedex      | 51.2 %               | 45.0 %  | 3.8 %                  |




# In vitro Fedex labeling of tumor cells


Labeling of U251 and U373 glioma cells, and H1 metastatic melanoma cells.




# SEM and TEM study of labeled tumor cells



# In vitro T2 Mapping of Tumor cells



24 hrs labeling





| #cells | T <sub>2</sub> NC | T <sub>2</sub> Fedex |      |      |      |     |     |             |
|--------|-------------------|----------------------|------|------|------|-----|-----|-------------|
| 4000   | 68,5              | 13,4                 |      |      |      |     |     | T2 Fedex    |
| 2000   | 67,3              | 20,2                 |      |      |      |     |     | T2 Control  |
| 1000   | 62,8              | 31,2                 |      |      |      |     |     | T2* Fedex   |
| 500    | 61,9              | 42,4                 |      |      |      |     |     | T2* Control |
| 250    | 61,5              | 51,5                 |      |      |      |     |     |             |
| 150    | 63,9              | 48,9                 |      |      |      |     |     |             |
| 100    | 65,4              | 54,2                 |      |      |      |     |     |             |
| 50     | 64,0              | 59,7                 |      |      |      |     |     |             |
|        |                   |                      | 4000 | 2000 | 1000 | 500 | 250 |             |




# In vivo MRI at single-cell level in a mouse model of melanoma cancer metastases to the brain

10  $\mu\text{g/ml}$  Fedex for 24 hrs




Intracardial injection of 1 mill cells

Detection of single cells 24 hrs after injection




Fedex

No Fedex



# Multiple brain metastases developed 7 weeks after injections



Between 20 and 30 metastases were observed by MR imaging 7 weeks after intracardial injections of the melanoma cells.



# Conclusions and future work

A new metastases growth model in the nude rat has been established, where human tumor tissue is operated directly into the animal brain.

The characterisation study shows that the animal brain metastases are similar to the patient brain metastases.

Future work: Treatment studies (Avastin, Gamma Knife)

We have established a model for studying the metastatic process of melanomas (H1 cell lines).

The H1 cell lines were tumorigenic when implanted intracranially, subcutaneously, or injected intracardially.

Future work: Repeat intracardial injections on larger number of mice. Genomic analysis, study of which ECM components are important for tumor cell migration and invasion.



# Acknowledgements

## **Department of Biomedicine, UiB**

Rolf Bjerkvig  
Inderjit Daphu  
Ingvild Wendelbo  
Jian Wang  
Jim Lorens  
David Mickelm  
Crina Tiron  
Anja Torsvik  
Agnete Svendsen  
Audun Dahlberg

**Department of Pathology,  
Haukeland University Hospital**  
Heike Immervoll

**Department of Internal Medicine  
Haukeland University Hospital**  
Emmet Mc Cormack

**Flow Cytometry Core Facility  
MIC**  
Marianne Enger

**Department of Neurosurgery,  
Haukeland University Hospital**  
Paal-Henning Pedersen